JP2011529032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529032A5 JP2011529032A5 JP2011519188A JP2011519188A JP2011529032A5 JP 2011529032 A5 JP2011529032 A5 JP 2011529032A5 JP 2011519188 A JP2011519188 A JP 2011519188A JP 2011519188 A JP2011519188 A JP 2011519188A JP 2011529032 A5 JP2011529032 A5 JP 2011529032A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pyridin
- added
- triazolo
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 0 *N(*)Cc(cc1)ccc1C(N1N)=CC=CC1=NC(NC(C1CC1)=O)=C Chemical compound *N(*)Cc(cc1)ccc1C(N1N)=CC=CC1=NC(NC(C1CC1)=O)=C 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- XLBCMNCPMMPNHH-UHFFFAOYSA-N n-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Chemical compound N=1N2C(Br)=CC=CC2=NC=1NC(=O)C1CC1 XLBCMNCPMMPNHH-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OQDLNQVZWBHIFC-UHFFFAOYSA-N 5-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl]pyridine-2-carbonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C(C=C1)=CC=C1OCC1=CC=C(C#N)N=C1 OQDLNQVZWBHIFC-UHFFFAOYSA-N 0.000 description 1
- -1 6-cyano-pyridin-3-ylmethoxy Chemical group 0.000 description 1
- UFWQIMQALLVHSQ-UHFFFAOYSA-N BC1[n]2nc(NC(C3CC3)=O)nc2C=CC1 Chemical compound BC1[n]2nc(NC(C3CC3)=O)nc2C=CC1 UFWQIMQALLVHSQ-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- PNVFKBFJINXDAM-ANHFWZFOSA-N CCC[C@H](C)/C=N\CCC#N Chemical compound CCC[C@H](C)/C=N\CCC#N PNVFKBFJINXDAM-ANHFWZFOSA-N 0.000 description 1
- MOPHSEMURIEBBJ-UHFFFAOYSA-N CC[n]1nnc(-c2cccc3nc(NC(C4CC4)O)n[n]23)c1 Chemical compound CC[n]1nnc(-c2cccc3nc(NC(C4CC4)O)n[n]23)c1 MOPHSEMURIEBBJ-UHFFFAOYSA-N 0.000 description 1
- PBOMCSWKMPCUKU-UHFFFAOYSA-N CN1N2C(C#C[Si](C)(C)C)=CC=CC2=NC1NC1OC1C1CC1 Chemical compound CN1N2C(C#C[Si](C)(C)C)=CC=CC2=NC1NC1OC1C1CC1 PBOMCSWKMPCUKU-UHFFFAOYSA-N 0.000 description 1
- UXGOYDMLNFSRTO-RXMQYKEDSA-N C[C@@](C1CC1)(N)O Chemical compound C[C@@](C1CC1)(N)O UXGOYDMLNFSRTO-RXMQYKEDSA-N 0.000 description 1
- BGYUZEKRNKAOPG-UHFFFAOYSA-N C[Si](C)(C)C#Cc1cccc2nc(NC(C3CC3)O)n[n]12 Chemical compound C[Si](C)(C)C#Cc1cccc2nc(NC(C3CC3)O)n[n]12 BGYUZEKRNKAOPG-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940080593 budesonide / formoterol Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229940114006 fluticasone / salmeterol Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- MDTMAUAPOMVGBI-UHFFFAOYSA-N n-[5-(2-trimethylsilylethynyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound N=1N2C(C#C[Si](C)(C)C)=CC=CC2=NC=1NC(=O)C1CC1 MDTMAUAPOMVGBI-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13592008P | 2008-07-25 | 2008-07-25 | |
| US61/135,920 | 2008-07-25 | ||
| US22068509P | 2009-06-26 | 2009-06-26 | |
| US61/220,685 | 2009-06-26 | ||
| PCT/EP2009/059604 WO2010010190A1 (en) | 2008-07-25 | 2009-07-24 | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529032A JP2011529032A (ja) | 2011-12-01 |
| JP2011529032A5 true JP2011529032A5 (enExample) | 2012-09-06 |
| JP5559168B2 JP5559168B2 (ja) | 2014-07-23 |
Family
ID=41021059
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519188A Active JP5559168B2 (ja) | 2008-07-25 | 2009-07-24 | 変性及び炎症性疾患の治療に有用な新規化合物 |
| JP2011519189A Active JP5480261B2 (ja) | 2008-07-25 | 2009-07-24 | 変性及び炎症性疾患の治療に有用な新規化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519189A Active JP5480261B2 (ja) | 2008-07-25 | 2009-07-24 | 変性及び炎症性疾患の治療に有用な新規化合物 |
Country Status (35)
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| NZ597140A (en) | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| CA2708690A1 (en) * | 2009-06-26 | 2010-12-26 | Markus Braun | Process for producing cellulose beads from solutions of cellulose in ionic liquid |
| WO2011140333A1 (en) | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| AR086042A1 (es) | 2011-04-28 | 2013-11-13 | Galapagos Nv | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica |
| SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
| US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| US9796719B2 (en) * | 2013-06-19 | 2017-10-24 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| ES2654051T3 (es) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas |
| KR20160100329A (ko) | 2013-12-20 | 2016-08-23 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물 |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| TWI679205B (zh) | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| CN107428749B (zh) | 2015-01-28 | 2020-07-24 | 上海复旦张江生物医药股份有限公司 | 取代的咪唑并[1,2-α]吡啶-2-基胺化合物及其药物组合物和使用方法 |
| JP2018511620A (ja) * | 2015-04-13 | 2018-04-26 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 炎症性障害の治療のための方法 |
| UA119701C2 (uk) * | 2015-04-29 | 2019-07-25 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Піримідинові сполуки як jak-інгібітори |
| AU2016257892A1 (en) * | 2015-05-05 | 2017-11-09 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
| CN105061420B (zh) * | 2015-06-04 | 2017-09-05 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
| CN104987333B (zh) * | 2015-07-14 | 2017-01-11 | 苏州富士莱医药股份有限公司 | 一种Filgotinib的合成方法 |
| WO2017012770A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Acid addition salts of filgotinib |
| WO2017012773A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Solid forms of filgotinib free base |
| WO2017012771A1 (en) | 2015-07-23 | 2017-01-26 | Ratiopharm Gmbh | Crystalline filgotinib sulfonic acid addition salts |
| CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
| CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
| CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
| CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
| CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
| CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
| CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
| CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
| WO2017133423A1 (zh) * | 2016-02-02 | 2017-08-10 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡啶酰胺类化合物及其应用 |
| TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| WO2018019223A1 (zh) * | 2016-07-26 | 2018-02-01 | 张文燕 | 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN107880038B (zh) * | 2016-09-30 | 2021-09-28 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
| TWI752098B (zh) * | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| AU2017350688B2 (en) * | 2016-10-26 | 2021-04-01 | Rapport Therapeutics, Inc. | Fused azaheterocyclic compounds and their use as AMPA receptor modulators |
| JP6953527B2 (ja) * | 2016-10-26 | 2021-10-27 | ヤンセン ファーマシューティカ エヌ．ベー． | 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用 |
| EA039344B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение |
| CN108341814B (zh) * | 2017-01-23 | 2021-09-03 | 上海翔锦生物科技有限公司 | Jak激酶抑制剂及其应用 |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN116730920A (zh) | 2017-02-17 | 2023-09-12 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
| SMT202400019T1 (it) | 2017-03-14 | 2024-03-13 | Galapagos Nv | Composizioni farmaceutiche comprendenti un inibitore jak |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| CN111479810B (zh) * | 2018-01-31 | 2022-11-22 | 珠海联邦制药股份有限公司 | Jak抑制剂及其应用 |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| CA3090545A1 (en) | 2018-02-28 | 2019-09-06 | University Of Southern California | Compositions and methods for modulating inflammatory and degenerative disorder |
| MA52137A (fr) | 2018-03-23 | 2021-01-27 | Eidos Therapeutics Inc | Méthodes de traitement de l'amylose ttr à l'aide d'ag10 |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| AU2019321583C1 (en) | 2018-08-17 | 2025-11-27 | Eidos Therapeutics, Inc. | Formulations of AG10 |
| PL3842431T3 (pl) | 2018-08-23 | 2024-05-20 | Zhuhai United Laboratories Co., Ltd. | Związek [1,2,4]triazolo[1,5-a]pirydyny jako inhibitor jak i jego zastosowanie |
| US10815227B2 (en) | 2018-08-27 | 2020-10-27 | Cadila Healthcare Limited | Processes for the preparation of filgotinib |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| EP3876930A4 (en) | 2018-11-07 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020097400A1 (en) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| KR20210108414A (ko) | 2018-12-25 | 2021-09-02 | 솔-겔 테크놀로지스 리미티드 | Egfr 억제제를 포함하는 조성물에 의한 피부 장애 치료 |
| CN114450274A (zh) | 2019-07-11 | 2022-05-06 | 伊斯凯普生物公司 | 作为lrrk2抑制剂的吲唑及氮杂吲唑 |
| CN111892592B (zh) * | 2019-08-06 | 2023-09-19 | 江苏柯菲平医药股份有限公司 | Jak激酶抑制剂及其用途 |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
| US12419873B2 (en) * | 2020-02-13 | 2025-09-23 | Zhuhai United Laboratories Co., Ltd. | Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases |
| AU2021222686B2 (en) * | 2020-02-21 | 2023-06-29 | Zhuhai United Laboratories Co., Ltd. | Crystalline form of JAK inhibitor and application thereof |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| CN111617318B (zh) * | 2020-05-26 | 2021-12-10 | 南京市儿童医院 | 可注射型儿童骺板再生水凝胶的制备方法 |
| CN114075188A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 芳香杂环酰胺类化合物及其制备方法和医药用途 |
| CN114075189A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 五元杂环并苯环类化合物及其制备方法和医药用途 |
| WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN114394965B (zh) * | 2021-01-29 | 2023-09-12 | 深圳市乐土生物医药有限公司 | 三唑并吡啶类化合物及其制备方法与用途 |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN113773322B (zh) * | 2021-11-10 | 2022-02-11 | 奥锐特药业(天津)有限公司 | 一种Filgotinib的制备方法 |
| CN116354955A (zh) * | 2021-12-28 | 2023-06-30 | 上海科胜药物研发有限公司 | 一种菲戈替尼的制备方法 |
| CN116496268A (zh) * | 2022-01-18 | 2023-07-28 | 盛世泰科生物医药技术(苏州)有限公司 | 一种含环丙酰胺化合物及其应用 |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
| US11746108B1 (en) * | 2022-06-13 | 2023-09-05 | Apm Therapeutics 1, Inc. | Triazolopyridine polymorph A |
| CN116687925B (zh) * | 2022-11-04 | 2024-10-22 | 中国科学院遗传与发育生物学研究所 | 一种侵蚀性蛋白酶抑制剂及其应用 |
| LU505465B1 (en) * | 2022-11-16 | 2024-05-14 | Adlai Nortye Biopharma Co Ltd | A pan-KRAS inhibitor compound |
| KR20260054550A (ko) * | 2024-10-15 | 2026-04-22 | 한국화학연구원 | JAK1를 선택적으로 저해하는 신규한 테트라하이드로이소퀴놀린 또는 이소인돌린 치환 [1,2,4]트리아졸로[1,5-a]피리딘 유도체 및 이의 용도 |
| CN119462650B (zh) * | 2024-11-20 | 2025-10-17 | 沈阳药科大学 | 一种非戈替尼的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE283840T1 (de) | 1999-01-29 | 2004-12-15 | Chugai Pharmaceutical Co Ltd | Chondrogonese promotoren und indolin-2-on derivate |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JP2006517580A (ja) | 2003-02-14 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗炎症化合物としてのトリアゾロピリジン |
| TWI221602B (en) * | 2003-07-21 | 2004-10-01 | Benq Corp | Emergent disc-withdrawing apparatus |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| JP2008503712A (ja) | 2004-06-21 | 2008-02-07 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨関節炎治療の方法及び手段 |
| JP2008509987A (ja) | 2004-08-18 | 2008-04-03 | ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー | トリアゾロピリジン化合物 |
| MX2007004179A (es) | 2004-10-07 | 2007-06-07 | Warner Lambert Co | Derivados de triazolpiridina como agentes antibacterianos. |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| ES2549862T3 (es) * | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| ATE495743T1 (de) * | 2006-12-01 | 2011-02-15 | Galapagos Nv | Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
| CL2008001626A1 (es) * | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| EP2178868A1 (en) * | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| MX2010002312A (es) * | 2007-08-31 | 2010-03-18 | Merck Serono Sa | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US8811196B2 (en) * | 2008-02-19 | 2014-08-19 | Qualcomm Incorporated | Providing remote field testing for mobile devices |
| US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
| US20100035875A1 (en) | 2008-06-20 | 2010-02-11 | Bing-Yan Zhu | Triazolopyridine jak inhibitor compounds and methods |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| ES2443307T3 (es) * | 2009-02-02 | 2014-02-18 | Basf Se | Absorbente que comprende aminas cíclicas para la eliminación de gases ácidos |
| DE102009000543A1 (de) * | 2009-02-02 | 2010-08-12 | Evonik Degussa Gmbh | Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen |
| NZ597140A (en) | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| HUE038878T2 (hu) | 2012-06-22 | 2018-12-28 | Galapagos Nv | Aminotriazolopirimidin gyulladás kezelésében történõ alkalmazásra és gyógyászati készítményeik |
-
2009
- 2009-07-12 JO JOP/2009/0259A patent/JO3041B1/ar active
- 2009-07-22 AR ARP090102793A patent/AR072875A1/es active IP Right Grant
- 2009-07-23 CL CL2009001637A patent/CL2009001637A1/es unknown
- 2009-07-23 TW TW098124908A patent/TWI447118B/zh not_active IP Right Cessation
- 2009-07-24 CN CN2009801291247A patent/CN102105472B/zh active Active
- 2009-07-24 BR BRPI0916659A patent/BRPI0916659B8/pt active IP Right Grant
- 2009-07-24 US US13/055,936 patent/US8853240B2/en active Active
- 2009-07-24 DK DK09781072.5T patent/DK2361251T3/da active
- 2009-07-24 JP JP2011519188A patent/JP5559168B2/ja active Active
- 2009-07-24 RS RS20140345A patent/RS53406B/sr unknown
- 2009-07-24 ES ES09781072.5T patent/ES2485913T3/es active Active
- 2009-07-24 WO PCT/EP2009/059604 patent/WO2010010190A1/en not_active Ceased
- 2009-07-24 PL PL09781072T patent/PL2361251T3/pl unknown
- 2009-07-24 EA EA201170257A patent/EA018587B1/ru not_active IP Right Cessation
- 2009-07-24 MX MX2011000756A patent/MX2011000756A/es active IP Right Grant
- 2009-07-24 ME MEP-2014-72A patent/ME02046B/me unknown
- 2009-07-24 MX MX2011000758A patent/MX2011000758A/es active IP Right Grant
- 2009-07-24 PE PE2009000989A patent/PE20100152A1/es active IP Right Grant
- 2009-07-24 RS RS20130214A patent/RS52823B/sr unknown
- 2009-07-24 MY MYPI20093101A patent/MY157615A/en unknown
- 2009-07-24 CA CA2730762A patent/CA2730762C/en active Active
- 2009-07-24 EP EP09781072.5A patent/EP2361251B1/en active Active
- 2009-07-24 JP JP2011519189A patent/JP5480261B2/ja active Active
- 2009-07-24 KR KR1020117004384A patent/KR101676391B1/ko not_active Expired - Fee Related
- 2009-07-24 KR KR1020117004383A patent/KR101711911B1/ko active Active
- 2009-07-24 SI SI200930973T patent/SI2361251T1/sl unknown
- 2009-07-24 HR HRP20130357AT patent/HRP20130357T1/hr unknown
- 2009-07-24 US US12/508,950 patent/US8242274B2/en active Active
- 2009-07-24 PT PT97810725T patent/PT2361251E/pt unknown
- 2009-07-24 BR BRPI0916862A patent/BRPI0916862B8/pt not_active IP Right Cessation
- 2009-07-24 CN CN200980129088.4A patent/CN102105471B/zh active Active
- 2009-07-24 ES ES09781073T patent/ES2406691T3/es active Active
- 2009-07-24 PL PL09781073T patent/PL2346864T3/pl unknown
- 2009-07-24 WO PCT/EP2009/059605 patent/WO2010010191A1/en not_active Ceased
- 2009-07-24 DK DK09781073.3T patent/DK2346864T3/da active
- 2009-07-24 AU AU2009273143A patent/AU2009273143B2/en active Active
- 2009-07-24 HR HRP20140681AT patent/HRP20140681T1/hr unknown
- 2009-07-24 EP EP09781073A patent/EP2346864B1/en active Active
- 2009-07-24 AU AU2009273144A patent/AU2009273144B2/en not_active Ceased
- 2009-07-24 UY UY0001032006A patent/UY32006A/es active IP Right Grant
- 2009-07-24 EA EA201170255A patent/EA018080B1/ru unknown
- 2009-07-24 SI SI200930582T patent/SI2346864T1/sl unknown
- 2009-07-24 NZ NZ590646A patent/NZ590646A/en not_active IP Right Cessation
- 2009-07-24 CA CA2730757A patent/CA2730757A1/en not_active Abandoned
- 2009-07-24 PT PT97810733T patent/PT2346864E/pt unknown
-
2010
- 2010-12-26 IL IL210261A patent/IL210261A/en active IP Right Grant
- 2010-12-26 IL IL210262A patent/IL210262A/en active IP Right Grant
-
2011
- 2011-01-14 ZA ZA2011/00396A patent/ZA201100396B/en unknown
- 2011-01-18 ZA ZA2011/00472A patent/ZA201100472B/en unknown
- 2011-01-18 DO DO2011000022A patent/DOP2011000022A/es unknown
- 2011-02-11 MA MA33602A patent/MA32551B1/fr unknown
- 2011-02-16 CR CR20110092A patent/CR20110092A/es unknown
- 2011-02-24 CO CO11022531A patent/CO6361925A2/es active IP Right Grant
-
2012
- 2012-08-10 US US13/572,043 patent/US20120309784A1/en not_active Abandoned
-
2013
- 2013-04-24 CY CY20131100335T patent/CY1113945T1/el unknown
- 2013-05-15 SM SM201300051T patent/SMT201300051B/xx unknown
-
2014
- 2014-06-17 SM SM201400072T patent/SMT201400072B/xx unknown
- 2014-07-29 CY CY20141100572T patent/CY1115569T1/el unknown
- 2014-10-06 US US14/507,396 patent/US9415037B2/en active Active
-
2016
- 2016-08-15 US US15/236,578 patent/US10206907B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529033A5 (enExample) | ||
| JP7604006B2 (ja) | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 | |
| US8796247B2 (en) | Indole derivative, and pharmacologically acceptable salt thereof | |
| US8815903B2 (en) | Indole derivative and pharmacologically acceptable salt thereof | |
| JP2016525072A5 (enExample) | ||
| AU2012333986B2 (en) | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities | |
| TW200808771A (en) | Novel compounds II | |
| JP2021502388A (ja) | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 | |
| IL235297A (en) | Dna-pk inhibitors, compositions comprising same and uses thereof | |
| TW202333714A (zh) | 包含喹唑啉化合物之醫藥組成物 | |
| CN101341149A (zh) | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 | |
| JP6019126B2 (ja) | 有機ニトロチオエーテル化合物およびその医療用途 | |
| US8710038B2 (en) | Pyrazole kinase modulators and methods of use | |
| CN104151292A (zh) | 吲哚衍生物或其可药用盐 | |
| JP5575357B2 (ja) | 組織因子産生抑制剤 | |
| JP2021527064A (ja) | Ｐｒｃ１阻害剤及びそれを用いた治療方法 | |
| CA2770766C (en) | Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones | |
| TW201536771A (zh) | 二環式含氮芳香族雜環醯胺化合物 | |
| Park et al. | Synthesis, biological evaluation and molecular modelling of 2, 4-disubstituted-5-(6-alkylpyridin-2-yl)-1 H-imidazoles as ALK5 inhibitors | |
| JP5584238B2 (ja) | インドール誘導体、またはその薬理学的に許容される塩の医薬用途 | |
| EP3440054B1 (en) | Pyrrole derivatives useful as mglur5 modulators | |
| US9464058B2 (en) | Imidazolylketone derivatives | |
| CN102579468B (zh) | 4位-1H-1，2，3-三唑-β-内酰胺衍生物的用途 | |
| CN119707980B (zh) | 一种抗肿瘤小分子药物偶联物包括pi3k抑制剂及其合成方法和应用 | |
| CN103896911A (zh) | 2-(3,4-二甲氧基)苯甲酰基-5-(4-取代苯乙炔基)噻吩及其制备方法及应用 |